Literature DB >> 18852281

Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.

Dong Yu1, Mallikarjuna R Putta, Lakshmi Bhagat, Meiru Dai, Daqing Wang, Anthony F Trombino, Tim Sullivan, Ekambar R Kandimalla, Sudhir Agrawal.   

Abstract

Oligodeoxynucleotides containing a CpG motif and double- or multistranded structure-forming sequences act as agonists of Toll-like receptor 9 (TLR9) and induce high levels of interferon alpha (IFN-alpha) in addition to other Th1-type cytokines. In the present study, we evaluated three highly effective IFN-alpha-inducing agonists of TLR9 to determine the type of duplex structures formed and the agonist's ability to induce immune responses, including IFN-alpha induction, in human cell-based assays and in vivo in mice and nonhuman primates. Thermal melting studies showed that two of the agonists evaluated had a single melting transition with similar hyperchromicity in both heating and cooling cycles, suggesting the formation of intermolecular duplexes. A third agonist showed a biphasic melting transition in the heating cycle and a monophasic melting transition with lower hyperchromicity during the cooling cycle, suggesting the formation of both intra- and intermolecular duplexes. All three agonists induced the production of Th1-type cytokines and chemokines, including high levels of IFN-alpha, in human peripheral blood mononuclear cell and plasmacytoid dendritic cell cultures. Subcutaneous administration of the two intermolecular duplex-forming agonists, but not the intramolecular duplex-forming agonist, induced cytokine secretion in mice. In nonhuman primates, the two agonists that formed intermolecular duplexes induced IFN-alpha and IP-10 secretion. On the contrary, the agonist that formed an intramolecular duplex induced only low levels of cytokines in nonhuman primates, suggesting that this type of structure formation is less immunostimulatory in vivo than the other structure. Taken together, the present results suggest that oligonucleotide-based agonists of TLR9 that form intermolecular duplexes induce potent immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852281      PMCID: PMC2592873          DOI: 10.1128/AAC.00701-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.

Authors:  Dong Yu; Ekambar R Kandimalla; Lakshmi Bhagat; Jin-Yan Tang; Yanping Cong; Jimmy Tang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

2.  Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.

Authors:  Gunther Hartmann; Julia Battiany; Hendrik Poeck; Moritz Wagner; Miren Kerkmann; Norbert Lubenow; Simon Rothenfusser; Stefan Endres
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

3.  Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells.

Authors:  Yan-Ping Cong; Sam S Song; Lakshmi Bhagat; Rajendra K Pandey; Dong Yu; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  Biochem Biophys Res Commun       Date:  2003-10-31       Impact factor: 3.575

Review 4.  Immunotherapeutic uses of CpG oligodeoxynucleotides.

Authors:  Dennis M Klinman
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

5.  Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Dong Yu; Yanping Cong; Jimmy Tang; Sudhir Agrawal
Journal:  Bioconjug Chem       Date:  2002 Sep-Oct       Impact factor: 4.774

6.  Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Authors:  Jörg Vollmer; Risini Weeratna; Paul Payette; Marion Jurk; Christian Schetter; Meike Laucht; Tanja Wader; Sibylle Tluk; Ming Liu; Heather L Davis; Arthur M Krieg
Journal:  Eur J Immunol       Date:  2004-01       Impact factor: 5.532

7.  Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions.

Authors:  Jason D Marshall; Karen Fearon; Christi Abbate; Sandhya Subramanian; Priscilla Yee; Josh Gregorio; Robert L Coffman; Gary Van Nest
Journal:  J Leukoc Biol       Date:  2003-06       Impact factor: 4.962

8.  Secondary structures in CpG oligonucleotides affect immunostimulatory activity.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Yan-Ping Cong; Rajendra K Pandey; Dong Yu; Qiuyan Zhao; Sudhir Agrawal
Journal:  Biochem Biophys Res Commun       Date:  2003-07-11       Impact factor: 3.575

9.  A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Fu-Gang Zhu; Dong Yu; Yan-Ping Cong; Daqing Wang; Jimmy X Tang; Jin-Yan Tang; Cathrine F Knetter; Egil Lien; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

10.  Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity.

Authors:  T Tokunaga; H Yamamoto; S Shimada; H Abe; T Fukuda; Y Fujisawa; Y Furutani; O Yano; T Kataoka; T Sudo
Journal:  J Natl Cancer Inst       Date:  1984-04       Impact factor: 13.506

View more
  5 in total

Review 1.  Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.

Authors:  Sudhir Agrawal; Ekambar R Kandimalla
Journal:  Immunooncol Technol       Date:  2019-10-16

Review 2.  Interferon-α and its effects on cancer cell apoptosis.

Authors:  Weiye Shi; Xu Yao; Yu Fu; Yingze Wang
Journal:  Oncol Lett       Date:  2022-05-30       Impact factor: 3.111

3.  Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.

Authors:  Cara Haymaker; Daniel H Johnson; Ravi Murthy; Salah-Eddine Bentebibel; Marc I Uemura; Courtney W Hudgens; Houssein Safa; Marihella James; Robert H I Andtbacka; Douglas B Johnson; Montaser Shaheen; Michael A Davies; Shah Rahimian; Srinivas K Chunduru; Denái R Milton; Michael T Tetzlaff; Willem W Overwijk; Patrick Hwu; Nashat Gabrail; Sudhir Agrawal; Gary Doolittle; Igor Puzanov; Joseph Markowitz; Chantale Bernatchez; Adi Diab
Journal:  Cancer Discov       Date:  2021-03-11       Impact factor: 39.397

4.  Characterization of genomic DNA of lactic acid bacteria for activation of plasmacytoid dendritic cells.

Authors:  Akira Horie; Yasuyuki Tomita; Konomi Ohshio; Daisuke Fujiwara; Toshio Fujii
Journal:  BMC Microbiol       Date:  2019-05-06       Impact factor: 3.605

Review 5.  CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.

Authors:  Zhongkun Zhang; Jimmy Chun-Tien Kuo; Siyu Yao; Chi Zhang; Hira Khan; Robert J Lee
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.